tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RNAC Stock Latest News

Cartesian Therapeutics announces employment inducement grants
The FlyCartesian Therapeutics announces employment inducement grants
18h ago
RNAC
Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections
PremiumRatings
Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections
2d ago
RNAC
Cartesian announces first participant enrolled in Phase 3 AURORA trial
PremiumThe Fly
Cartesian announces first participant enrolled in Phase 3 AURORA trial
5d ago
RNAC
Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho
PremiumThe Fly
Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho
23d ago
RNAC
Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising mRNA-Based CAR-T Developments and Strategic Clinical Advancements
PremiumRatings
Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising mRNA-Based CAR-T Developments and Strategic Clinical Advancements
23d ago
RNAC
Promising Potential of Cartesian Therapeutics’ Descartes-08 Therapy Drives Buy Rating
PremiumRatingsPromising Potential of Cartesian Therapeutics’ Descartes-08 Therapy Drives Buy Rating
23d ago
RNAC
Cartesian Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Cartesian Therapeutics Reports Q1 2025 Financial Results
26d ago
RNAC
Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook
Premium
Ratings
Buy Rating for Cartesian Therapeutics: Promising Clinical Progress and Stable Financial Outlook
27d ago
RNAC
Cartesian Therapeutics reports Q1 EPS (68c) vs ($10.50) last year
PremiumThe Fly
Cartesian Therapeutics reports Q1 EPS (68c) vs ($10.50) last year
27d ago
RNAC
RNAC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
RNAC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
30d ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe Fly
Cartesian Therapeutics announces employment inducement grants
1M ago
RNAC
Cartesian Therapeutics CTO Transition to Consultant Role
PremiumCompany Announcements
Cartesian Therapeutics CTO Transition to Consultant Role
1M ago
8K
RNAC
Cartesian Therapeutics management to meet with BTIG
PremiumThe FlyCartesian Therapeutics management to meet with BTIG
1M ago
RNAC
Seven new option listings and one option delisting on April 16th
Premium
The Fly
Seven new option listings and one option delisting on April 16th
2M ago
AVTX
CARA
Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile
Premium
Ratings
Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile
2M ago
RNAC
Promising Growth Potential for Cartesian Therapeutics: Buy Rating Affirmed by Analyst Gil Blum
PremiumRatings
Promising Growth Potential for Cartesian Therapeutics: Buy Rating Affirmed by Analyst Gil Blum
2M ago
RNAC
Promising Potential of Cartesian Therapeutics’ Descartes-08 in gMG Treatment: A Buy Recommendation
PremiumRatings
Promising Potential of Cartesian Therapeutics’ Descartes-08 in gMG Treatment: A Buy Recommendation
2M ago
RNAC
Promising Clinical Data and Future Prospects Drive Buy Rating for Cartesian Therapeutics
PremiumRatings
Promising Clinical Data and Future Prospects Drive Buy Rating for Cartesian Therapeutics
2M ago
RNAC
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results
PremiumCompany Announcements
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results
2M ago
8K
RNAC
Cartesian Therapeutics announces data from Phase 2b trial of Descartes-08
PremiumThe FlyCartesian Therapeutics announces data from Phase 2b trial of Descartes-08
2M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
Premium
The Fly
Cartesian Therapeutics announces employment inducement grants
2M ago
RNAC
Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress
Premium
Ratings
Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress
3M ago
RNAC

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >